{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 36,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a three-column layout to summarize key strategic pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/3",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.21
      },
      "kind": "list",
      "text": "Conviction with Epetraborole in NTM; Near-Term Catalysts Disciplined Capital Spend; Proven Boron Based Discovery Platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39ec8977-2097-481c-8156-f0bdc80a3bc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.66,
        "y": 0.39
      },
      "kind": "list",
      "text": "Founded by AN2 team originally from Anacor; Established record of platform productivity (Novel targets, 2 FDA approved drugs, 1 pending, Anacor sold to Pfizer for $5.2B); Opportunity to identify novel targets beyond oncology and ID",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f2b431c-d8ed-4d23-a7f6-801e307d2694",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.36,
        "y": 0.39
      },
      "kind": "list",
      "text": "EBO: Phase 3 unblinding 2Q25; Chagas: Initiate Phase 1 mid-2025; Melioidosis: Start Ph 2 2H25; Initiate development for two compounds (oncology and ID)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb9d200c-1bc2-4fdc-989f-9bb26fe7c6ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.06,
        "y": 0.39
      },
      "kind": "paragraph",
      "text": "Epetraborole showed potential for clinical improvement in two PROs: QOL-B and MACrO2 using continuous score method. Selected QOL-B as new Phase 3 Primary Efficacy Endpoint. Goal to unblind Phase 3 data in 2Q25 ahead of potential FDA meeting.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "306a3fef-0b74-444a-aebe-11c273d67062",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.23,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "EBO= Epetraborole; EOP-2= End of Phase 2 meeting; ID= Infectious disease; MACrO2= Mycobacterium avium complex respiratory outcomes 2; PRO= Patient reported outcome; QOL-B= Quality of Life – Bronchiectasis; TR-MAC= Treatment-refractory Mycobacterium avium complex",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92d4eda2-a41c-4c8c-aa12-eb9a55f4c734",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Advancing Novel Therapies With Our Boron Chemistry Platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9b7fb48-173a-45e0-89f4-f4957c3d7a73",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "87af36fd-d6fb-4c83-a16c-e49fee13ba23",
      "evidence": "components: paragraph/paragraph: Epetraborole showed potential for clinical improvement in two PROs: QOL-B and MACrO2 using continuous score method.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}